Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos has acquired Sareum Holdings's assets in drug discovery services, for a total cash consideration of E695,000. These assets are expected to position Galapagos's service division BioFocus DPI strongly in the growing field of structure-based drug discovery.
Subscribe to our email newsletter
Under the agreement, Galapagos has acquired all of Sareum’s ongoing services contracts relating to structure-based drug discovery, the Crystal Bank, a fragment screening library and the specialized equipment needed to perform structure-based drug discovery.
According to Galapagos, the acquired technology will be incorporated within BioFocus DPI’s capabilities in screening and medicinal chemistry, and will complement its services offering. A team of five Sareum employees will join BioFocus DPI (Chesterford Park, Saffron Walden, UK) and continue to operate the platform, securing a smooth transition of the business.
Tim Mitchell, CEO of Sareum Holdings, said: “I am confident that the acquisition of Sareum’s expertise in structure-based drug discovery services will further enhance BioFocus DPI’s leading position in global drug discovery service provision.”